Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

Emmanuel Dulac is leaving his post as chief international strategy officer of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to become the new CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL), effective April 22. Dulac succeeds Adam Steensberg,

Read the full 345 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE